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0163-7258/© 2018 Elsevier Inc. All rights reserved.a b s t r a c ta r t i c l e i n f oAvailable online 18 February 2018 Inﬂammasomes are intracellular multiprotein signaling complexes, mainly present in myeloid cells. They
commonly assemble around a cytoplasmic receptor of the nucleotide-binding leucine-rich repeat containing
receptor (NLR) family, althoughother cytoplasmic receptors like pyrinhave been shown to form inﬂammasomes.
The nucleation of the multiprotein scaffolding platform occurs upon detection of a microbial, a danger
or a homeostasis pattern by the receptor that will, most commonly, associate with the adaptor protein ASC
(apoptosis-associated speck-like protein containing a CARD) through homotypic domain interactions resulting
in recruitment of procaspase-1. This will lead to the autoproteolytic activation of caspase-1, which regulates
the secretion of proinﬂammatory IL1β and IL18 cytokines and pyroptosis, a caspase-1-mediated form of
cell death. Pyroptosis occurs through cleavage of Gasdermin D, a membrane pore forming protein. Recently,
non-canonical inﬂammasomes have been described, which directly sense intracellular pathogens through
caspase-4 and -5 in humans, leading to pyroptosis.
Inﬂammasomes are important in host defense; however, a deregulated activity is associated with a number of
inﬂammatory, immune and metabolic disorders. Furthermore, mutations in inﬂammasome receptor coding
genes are causal for an increasing number of rare autoinﬂammatory diseases. Biotherapies targeting the products
of inﬂammasome activation aswell as molecules that directly or indirectly inhibit inﬂammasome nucleation and
activation are promising therapeutic areas. This review discusses recent advances in inﬂammasome biology, the
molecular pathology of several inﬂammasomes, and current therapeutic approaches in autoinﬂammatory
diseases and in selected common multifactorial inﬂammasome-mediated disorders.
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Inﬂammasomes are caspase-1-dependent and -independent
multiprotein platforms which nucleate around an intracellular receptor
that typically belongs to the family of Nucleotide-binding, Leucine-rich
Repeat containing proteins (NLRs). Inﬂammasome components are
principally expressed in innate immune cells such as monocytes
and macrophages (Awad et al., 2017), but also in dendritic cells and
neutrophils (Bakele et al., 2014; Sharp et al., 2009), as well as in certain
non-immune cells, such as keratinocytes (Feldmeyer et al., 2007).
Inﬂammasome association and activity is triggered upon detection
of microbial products, sterile endogenous danger signals or upon
the more recently described alterations in homeostasis, known under
the names of pathogen- or danger-associated molecular patterns or
homeostasis-altering molecular processes (PAMPs or DAMPs or
HAMPs, respectively) (Liston & Masters, 2017; Martinon, 2008).
Inﬂammasomes, play major roles in host defence against intracellular
bacteria and viruses (Vanaja, Rathinam, & Fitzgerald, 2015) and in the
regulation of inﬂammation (Próchnicki & Latz, 2017; Robbins, Wen, &
Ting, 2014) through pro-inﬂammatory cytokine secretion. Mutations
in inﬂammasome genes are causal for an increasing number of self-
directed inﬂammatory diseases termed autoinﬂammatory diseases
(McGonagle & McDermott, 2006). A deregulated inﬂammasome activ-
ity has also been reported in common metabolic, immune and inﬂam-
matory disorders (Davis, Wen, & Ting, 2011; de Zoete, Palm, Zhu, &
Flavell, 2014; Guo, Callaway, & Ting, 2015; Lamkanﬁ, Walle, &
Kanneganti, 2011; Robbins et al., 2014). Biotherapies targeting
inﬂammasome-mediated cytokine release and pharmacological inhibi-
tors that interfere with inﬂammasome nucleation and activation are
promising therapeutic areas in inﬂammatory diseases. In the current
review, we will discuss the biology, the molecular pathology and thera-
peutic implications of selected inﬂammasomes in autoinﬂammatory
diseases, as well as in several common multifactorial inﬂammasome-
mediated disorders.
2. The key inﬂammasome players
2.1. Nucleotide-binding, leucine-rich repeat containing receptors (NLRs)
NLRs are a group of germline-encoded innate immune receptors
present in the cytoplasm of immune cells (Janeway & Medzhitov,
2002) which are involved in microbial recognition and host defence.
In humans, 22 evolutionarily conserved NLRs are known today, several
ofwhich are implicated in inﬂammatory diseases (Zhong, Kinio, & Saleh,
2013). These proteins contain several domains: a central nucleotide-
binding and oligomerisation domain, also known as NOD or NACHT —
standing for NAIP (neuronal apoptosis inhibitor protein), CIITA (MHC
class II transcription activator), HET-E (incompatibility locus protein
from Podospora anserina) and TP1 (telomerase-associated protein) —,
required for ATP-dependent self-oligomerization, a NACHT-associated
domain (NAD) and a C-terminal leucine-rich repeat (LRR) domain
potentially implicated in ligand detection. The N-terminal domain is
variable and subdivides the family into at least 5 groups (Chen, Shaw,
Kim, & Nuñez, 2009; Ting et al., 2008) (Fig. 1). The NLRA group isdeﬁned by the presence of an acidic transactivation domain, whereas
the NLRB group contains baculovirus inhibitor repeats (BIRs). The
NLRC group is deﬁned by the presence of a caspase recruitment domain
(CARD), whereas the presence of a pyrin (PYD) domain is speciﬁc to
the largest group called NLRP. Finally, the NLRX group contains
NLRX1, a protein that lacks both PYD and CARD domains, with an
atypical N-terminal domain which contains a mitochondrial-targeting
sequence (Arnoult et al., 2009; Moore et al., 2008). The N-terminal do-
main of NLRs mediates homotypic interactions with other proteins. In
this regard, the presence of an N-terminal domain like a PYD or a
CARD, which are members of the six-helix death domain-fold
superfamily, is crucial tomediate inﬂammatory and apoptotic signalling
pathways via the activation of caspases.2.2. Inﬂammasome forming NLRs
Upon detection of a molecular pattern (PAMP, DAMP, or HAMP),
NLRs associate in multiprotein complexes called inﬂammasomes
that mediate caspase-1 activation and cytokine secretion (Fig. 2). An
increasing number of NLR family members have been shown to form
inﬂammasomes (Fig. 1). Inﬂammasome assembly is guided by
homotypic interactions between the PYD domain of the receptor
(commonly but not exclusively from the NLRP family) and the adaptor
protein ASC (Apoptosis-associated Speck-like protein containing a
CARD) which, through CARD-CARD domain interactions recruits pro-
caspase-1 into the complex (see below). This leads to an active
caspase-1 heterotetramer that proteolytically processes the zymogen
forms of IL1β and IL18 pro-inﬂammatory cytokines, leading to their
maturation and secretion (Martinon & Tschopp, 2004; Thornberry
et al., 1992). In the case of NLRs that contain both a CARD and a PYD do-
mains like NLRP1, or NLRs with a CARD domain like NLRC4, the interac-
tion between the NLR and pro-caspase can, in some cases, occur in the
absence of ASC (Broz, von Moltke, Jones, Vance, & Monack, 2010;
Faustin et al., 2007; Mariathasan et al., 2004; Yu, Moecking, Geyer, &
Masters, 2017). In this review, among the inﬂammasome forming
NLRs, we will focus on the NLRP3 inﬂammasome, which is the best-
characterized inﬂammasome nucleating around an NLR; we shall
equally discuss the NLRP12 inﬂammasome whose existence remains
controversial.2.3. Non-NLR proteins forming inﬂammasomes
Inﬂammasomes can also nucleate around non-NLR proteins as ﬁrst
shown with AIM2 (Absent In Melanoma-2), a cytoplasmic protein not
belonging to the NLR family. AIM2 contains an N-terminal PYD domain
and in response to double stranded cytosolic DNA, is able to form an
inﬂammasome (Fernandes-Alnemri, Yu, Datta, Wu, & Alnemri, 2009;
Hornung & Latz, 2010a). This is also the case for three other non-NLR
proteins, the interferon-inducible protein 16 (IFI-16) (Kerur et al.,
2011), the retinoic acid inducible gene I (RIG-1) (Pothlichet et al.,
2013) and pyrin (Xu et al., 2014). In this review, we will also discuss
the inﬂammasome nucleating around the PYD domain of pyrin.
Fig. 1. The humanNLR family. The NLR family is sub-divided into at least ﬁve subgroups (NLRA, NLRB, NLRC, NLRP and NLRX) based on the nature of the N-terminal effector domain. The NLRA
group is deﬁned by the presence of an acidic transactivation domain (AD),whereas theNLRB group contains baculovirus inhibitor repeats (BIRs). TheNLRC group is deﬁned by the presence of a
caspase recruitment domain (CARD), whereas the largest group, termedNLRP, is characterized by the presence of a pyrin (PYD) domain. The NLRX group contains NLRX1, a protein that has an
atypical N-terminal domain which contains a mitochondrial-targeting sequence. A central nucleotide-binding and oligomerization domain (called NACHT or NOD) and a C-terminal LRR
(leucine-rich repeat) domain are common to all members with the exception of NLRP10 that lacks the LRR domain. NAD: (NACHT-associated domain); FIIND: (function to ﬁnd domain).
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ASC, also known as PYCARD, is a bipartite protein with two death-
fold interaction domains, the N-terminal PYD and the C-terminal
CARD domains. Its unique structure makes ASC an important adaptorFig. 2. Basic steps in inﬂammasome formation and action. DAMPs, PAMPs or HAMPs
activate the inﬂammasome sensor usually from the NLR family. This leads to the adaptor
protein ASC and pro-caspase-1 recruitment leading to the formation of the
inﬂammasome complex. Inﬂammasome activates caspase-1 which then proteolytically
maturates pro IL1β and pro-IL18 leading to their secretion. Caspase 1 can also cleave
Gasdermin D leading to pyroptosisprotein bringing together PYD- and CARD-containing proteins
(Gumucio et al., 2002). ASC was ﬁrst identiﬁed in large cytosolic
hollow-centred aggregates termed “specks” in the human
promyelocytic cell line HL60 undergoing apoptosis (Masumoto et al.,
1999). ASC specks are around 1 μm, visible under the microscope, and
usually one speck per cell is seen upon inﬂammasome activation
(Beilharz, De Nardo’s, Latz, & Franklin, 2016; Fernandes-Alnemri et al.,
2007; Stutz, Horvath, Monks, & Latz, 2013). ASC specks involve
oligomerization of ASC through their PYD domains into ﬁlaments and
cross-linking of theseﬁlaments by the CARDdomains of ASC. These olig-
omers create caspase-1 activation sites, amplifying inﬂammasome-
mediated signalling (Dick, Sborgi, Rühl, Hiller, & Broz, 2016). In this
regard, speck formation is often used as a read-out for inﬂammasome
activation (Jéru et al., 2010; Stutz et al., 2013). Interestingly, oligomeric
ASC particles have also been found in the extracellular space and in the
serum of patients with several autoinﬂammatory diseases suggesting
that the particles per semay act as danger signals amplifying the inﬂam-
matory response (Baroja-Mazo et al., 2014; Franklin et al., 2014).
2.5. Non-inﬂammasome forming NLRs involved in inﬂammation
As mentioned above, several NLRs form inﬂammasomes; however,
some NLR members such as NOD1/NLRC1, NOD2/NLRC2 and NLRX1
activate downstream inﬂammatory signalling through engagement of
nuclear factor-κB (NF-κB), mitogen-activated protein kinases (MAPKs)
and interferon regulatory factors (IRFs) without being implicated in
multiprotein complexes (Zhong et al., 2013). NLRX1 has a unique
mitochondrial localization (Arnoult et al., 2009) and although the
N-terminal domain is still not well characterized, it has been
shown to regulate interferon and NF-κB signalling (Moore et al.,
2008; Tattoli et al., 2008). In epithelial cells, Chlamydia trachomatis
infection activates reactive oxygen species (ROS) production. Interest-
ingly, ROS production is induced by NLRX1 and confers optimal growth
conditions forChlamydia trachomatis (Abdul-Sater et al., 2010). In another
study, NLRX1, in interaction with TUFM (mitochondrial Tu translation
elongation factor) another mitochondrial protein, stimulated autophagy
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results suggest that further studies are required in order to understand
the function of non-inﬂammasome-forming NLRs in inﬂammation.
3. The canonical and non-canonical inﬂammasomes
In the so-called “canonical inﬂammasome”, caspase-1 plays a central
role (Fig. 3, middle panel). Proximity-induced oligomerization of
caspase-1 in the inﬂammasome enables its activation and
autoproteolysis leading to p20/p10 caspase-1 dimers that associate in
tetramers in solution (Boatright et al., 2003; Elliott, Rouge, Wiesmann,
& Scheer, 2009; Walker et al., 1994). The enzymatically active dimers
subsequently cleave pro-IL1β and pro-IL18 to their biologically active
forms. Both cytokines play an important role in systemic inﬂammation
due to their ability to act on various target organs and to induce the ex-
pression of a large panel of pro-inﬂammatory genes thereby amplifying
the inﬂammatory response (Cerretti et al., 1994; Dinarello, 1997;Fig. 3. Canonical, non-canonical and alternative inﬂammasomes. Left panel: non-canonical inﬂa
by the CARD domain of caspase 4/5 in humans (the exact mechanism of interaction is still not
gasderminD, amembrane-pore-forming protein leading to cell swelling andmembrane rupture
inﬂammasome. The canonical NLRP3 inﬂammasome is activated by a TLR signal (LPS is the mo
IL1β. *A post-transcriptional modiﬁcation is also possible and involves deubiquitination of NLR
with caspase-1 activation, followed by thematuration of pro-IL1β andpro-IL18 and the release o
a lytic death called pyroptosis through the cleavage of gasdermin D, a membrane-pore-formin
alarmins and proinﬂammatory cytokines in the extracellular space. Common mechanism
concentrations, mitochondrial damage, lysosomal destabilization. DAMP: (Danger Associated M
altering molecular processes). The arrow in grey indicates interactions between the non-can
NLRP3-dependent IL1β and IL18 secretion. Right panel: alternative inﬂammasome. The NL
(oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine) or N-acetylglycosa
pyroptosis.Garlanda, Dinarello, & Mantovani, 2013; Keller, Rüegg, Werner, & Beer,
2008; Martinon, Burns, & Tschopp, 2002; Okamura, Tsutsui,
Kashiwamura, Yoshimoto, & Nakanishi, 1998; Schmitz et al., 2005). In
addition, inﬂammasome activation leads to a distinct form of lytic
death called pyroptosis. Pyroptosis induction was recently shown to
be linked to gasdermin-D (GSDMD), a protein with membrane pore-
forming activity (Kayagaki et al., 2015; Liu et al., 2016). Caspase-1-
dependent cleavage of GSDMD liberates the pro-pyroptotic N-
terminal domain from an inhibitory interaction with the C-terminal
domain of the protein. Once generated, the N-terminal part of
GSDMD targets the cytoplasmic face of the plasma membrane, due to
its afﬁnity for phospholipids like phosphorylated phosphatidylinositols
and cardiolipin (Liu et al., 2016). Accumulation and oligomerization of
the N-terminal part of GSDMD leads to pore formation (Aglietti et al.,
2016; Ding et al., 2016; Sborgi et al., 2016). The subsequent loss of
membrane integrity allows small intracellular molecules such as pro-
inﬂammatory cytokines and different alarmins to be releasedmmasome. LPS enters the cytoplasm by unknownmechanisms. LPS is directly recognized
understood) leading to caspase oligomerization and activation. Active caspase 4/5 cleaves
accompanied by the release of alarmins in the extracellular space.Middle panel: canonical
st commonly used experimentally), which induces transcriptional activation of NLRP3 and
P3. A second signal (DAMP, PAMP or HAMP) leads to NLRP3 oligomerization (not shown),
f themature forms of these pro-inﬂammatory cytokines. Caspase-1 activation also induces
g protein leading to cell swelling and membrane rupture accompanied by the release of
s which promote NLRP3 inﬂammasome activation include alteration in K+ or Ca2+
olecular Pattern); PAMP: (Pattern Associated Molecular Pattern); HAMP: (homeostasis-
onical and the canonical inﬂammasome as the non-canonical inﬂammasome mediates
RP3 inﬂammasome is activated by LPS or other molecules that mimic LPS like OxPAPC
mine leading to caspase-1 activation and release of IL1β and IL18 without K+ efﬂux or
137F. Awad et al. / Pharmacology & Therapeutics 187 (2018) 133–149(Aachoui, Sagulenko, Miao, & Stacey, 2013; Fink & Cookson, 2007;
Lamkanﬁ et al., 2011). The liberation of the intracellular content on
the one hand leads to pathogen clearance (Miao et al., 2010; Miao,
Rajan, & Aderem, 2011), but excessive pyroptosis activation, on the
other hand, can be detrimental for the host (Bergsbaken, Fink, &
Cookson, 2009).
The observation that, in mouse macrophages, Gram-negative
bacteria induce pyroptosis through caspase-11 without requiring the
Nlrp3-Asc-caspase-1 pathway paved the route for the discovery of a
non-canonical, caspase-11-dependent inﬂammasome (Hagar, Powell,
Aachoui, Ernst, & Miao, 2013; Kayagaki et al., 2013) (Fig. 3, left
panel). In humans, caspase-1-independent inﬂammasomes employ
pro-inﬂammatory caspase-4 and -5, which are the closest homologues
to murine caspase-11 (Lamkanﬁ, Declercq, Kalai, Saelens, &
Vandenabeele, 2002). The discovery that caspase-4 and -5 are activated
by direct binding to intracellular LPSwithout the requirement of anNLR
or ASC suggested that pathogens may escape innate surveillance
through receptors present in the plasma membrane and invade the
host cell leading to infection (Shi et al., 2014). Intracellular LPS sensing
in human monocytes and macrophages leads to caspase-4 mediated
pyroptosis (Shi et al., 2014). Similar results have been found in endothe-
lial and epithelial cells as well as in keratinocytes (Casson et al., 2015;
Kayagaki et al., 2013; Knodler et al., 2014; Shi et al., 2014), suggesting
the implication of non-myeloid cells in pathogen detection. Among
the structural moieties of LPS, the conserved lipid A is the part consid-
ered responsible for non-canonical inﬂammasome activation through
interactionwith the CARD domain of caspase-4 and -5. Caspase-4 tissue
expression is wider than that of caspase-5 (Lin, Choi, & Porter, 2000),
potentially suggesting cell/tissue-speciﬁc roles for each caspase (Lin
et al., 2000; Salskov-Iversen, Johansen, Kragballe, & Iversen, 2011).
Whether or not both caspases are required for the intracellular
detection of LPS is so far unknown. Caspase-4/-5 may also regulate the
secretion of IL1α and other cytokines in certain cells types (Yang,
Zhao, & Shao, 2015). Interestingly, active caspase-4 and -5 in humans
or caspase-11 in mice also induce NLRP3-mediated IL1β secretion
through a pyroptosis-mediated mechanism (Baker et al., 2015). In that
situation, cell-intrinsic mechanisms like potassium efﬂux (Rühl & Broz,
2015; Schmid-Burgk et al., 2015) activate NLRP3, thereby unveiling in-
teractions between the canonical and non-canonical inﬂammasomes
(Lamkanﬁ & Dixit, 2014).
4. The NLRP3 inﬂammasome: activation and regulation
The inﬂammasome that nucleates aroundNLRP3 is themost studied.
NLRP3 is primarily expressed in cells of the myelomonocytic lineage
(Feldmann et al., 2002; Hoffman, Mueller, Broide, Wanderer, &
Kolodner, 2001; Manji et al., 2002) and its mRNA and protein levels
are up-regulated in monocytes and macrophages upon exposure to in-
ﬂammatory stimuli (Awad et al., 2017; O’Connor, Harton, Zhu, Linhoff,
& Ting, 2003). NLRP3 expression has also been reported in B and T
lymphocytes (Kummer et al., 2007), in epithelial cells lining the oral
and genital tracts, in skin keratinocytes (weak expression) (Kummer
et al., 2007), as well as in chondrocytes (Feldmann et al., 2002).
4.1. Classical activation of the NLRP3 inﬂammasome
For an active inﬂammasome, a two-step process is required (Fig. 3,
middle panel). The ﬁrst step/signal, which also is known as the priming
signal, is usually a bacterial component like LPS that induces NLRP3 and
IL1B transcription. Basal expression of NLRP3 is not sufﬁcient for
inﬂammasome activation in resting cells. It has been shown that the
amount of NLRP3 mRNA is tightly regulated by the myeloid-speciﬁc
microRNA-223 (miR-223), which is expressed in monocytes and leads
to decreased NLRP3 protein levels, thus inﬂuencing the threshold of
NLRP3 activation (Haneklaus et al., 2012). Post-translational modiﬁca-
tions of NLRP3 such as ubiquitin modiﬁcations have also been reportedto regulate NLRP3 (Juliana et al., 2012; Kattah, Malynn, & Ma, 2017; Py,
Kim, Vakifahmetoglu-Norberg, & Yuan, 2013; Song et al., 2016). Juliana
et al. showed that, in primary mouse macrophages, signalling through
the Toll-like receptor results in Nlrp3 priming by stimulation of its
deubiquitination, itself dependent on mitochondrial ROS (Juliana et al.,
2012). ATP can also trigger NLRP3 deubiquitination but through a
mitochondrial ROS-independent mechanism (Juliana et al., 2012).
Subsequently, Py et al. identiﬁed Brcc3 as the mouse deubiquitinase
that regulates Nlrp3 by speciﬁcally interacting with the ubiquitinated
LRR domain of Nlrp3 (Py et al., 2013). In addition, as shown by Song
et al., the E3 ubiquitin ligase Trim 31 attenuates Nlrp3 inﬂammasome
activation by promoting proteasomal degradation of Nlrp3 in both
resting and activated mouse macrophages (Song et al., 2016).
The second signal promotes the association of the inﬂammasome
components to create a functional inﬂammasome with translation and
secretion of the mature IL1β protein (Bryant & Fitzgerald, 2009). The
second signal can be of variable nature (PAMPS, DAMPs or HAMPs).
Various activators of the NLRP3 inﬂammasome have indeed been
identiﬁed such as Gram-positive bacteria (like Staphylococcus aureus
and Group B Streptococcus), Gram-negative bacteria (like Citrobacter
rodentium, Escherichia coli, or Vibrio cholerae), viruses (like Inﬂuenza
virus), the bacterial toxin nigericin, pore-forming toxins like hemolysin
and pneumolysin, environmental nanoparticles like silica, asbestos or
alum, and cellular damage molecules like ATP, β-amyloid aggregates,
monosodium urate (MSU) and cholesterol crystals (Bauernfeind et al.,
2009; Bryant & Fitzgerald, 2009; Costa et al., 2012; Duncan et al.,
2009; Elliott & Sutterwala, 2015; Franchi, Muñoz-Planillo, & Núñez,
2012; Ichinohe, Pang, & Iwasaki, 2010; Kingsbury, Conaghan, &
McDermott, 2011; Koizumi et al., 2012; Lupfer & Kanneganti, 2013;
Mariathasan et al., 2006; Sutterwala, Ogura, & Flavell, 2007; Vanaja
et al., 2015).
How exactly all these diverse danger signals trigger the same
inﬂammasome sensor remains unclear. Their highly variable structures
suggest that NLRP3 senses them indirectly. Cellular stress or altered
homeostasis signals are considered as intermediate steps resulting in
NLRP3 inﬂammasome activation (Latz, 2010; Liston & Masters, 2017).
The most prevailing inﬂammasome activating mechanism involves
changes in cytosolic K+ concentration (Pétrilli et al., 2007; Yaron et al.,
2015). In this line, DAMPs like ATP, which engage the purinergic recep-
tor P2X7, or bacterial pore-forming toxins, induce cytosolic K+ efﬂux
(Di Virgilio, 2007, 2013; Muñoz-Planillo et al., 2013). The decreased in-
tracellular K+ levels trigger NLRP3 inﬂammasome activation. A second
mechanism concerns crystalline or particulate structure DAMPs, (such
as β-amyloid aggregates, MSU and cholesterol crystals) which, after
being phagocytosed by immune cells induce lysosomal swelling and
damage (Dostert et al., 2008; Halle et al., 2008; Hornung et al., 2008;
Hornung & Latz, 2010b). The subsequent release of lysosomal proteases
like cathepsin B activates NLRP3 inﬂammasome. A third mechanism
suggests an important role for mitochondria in NLRP3 inﬂammasome
activation (Nakahira et al., 2011; Shimada et al., 2012; Subramanian,
Natarajan, Clatworthy, Wang, & Germain, 2013; Tschopp & Schroder,
2010; Zhou, Yazdi, Menu, & Tschopp, 2011). Mitochondrial ROS activate
thioredoxin-interacting protein (TXNIP) that, in turn, binds to and
activates the NLRP3 inﬂammasome (Zhou, Tardivel, Thorens, Choi, &
Tschopp, 2010). Apart from ROS generation, mitochondrial movement
along microtubules (Misawa et al., 2013), altered mitochondrial
elongation and ﬁssion (Park et al., 2015) and defective mitophagy
(Zhong et al., 2016) can also regulate NLRP3 inﬂammasome activation.
A fourth mechanism links NLRP3 inﬂammasome activation to alter-
ations in intracellular calcium concentration. The transcription factor
C/EPB homologous protein (CHOP, also known as DDIT3), whichmodu-
lates calcium mobilization from the endoplasmic reticulum (ER),
ampliﬁes inﬂammasome activation in LPS-primedmousemacrophages,
linking ER stress to activation of the NLRP3 inﬂammasome (Murakami
et al., 2012). Activation of the calcium-sensing receptor (CASR) activates
the NLRP3 inﬂammasome through increased intracellular calcium or
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pholipase C which through production of inositol-1,4,5-trisphosphate
(IP3) induces liberation of calcium from ER resulting in NLRP3 activa-
tion (Lee et al., 2012). Intracellular calcium is important for spontaneous
IL1β secretion in cells from patients with mutations in NLRP3 (Lee et al.,
2012). In addition, extracellular calcium can also act as a DAMP to in-
duce NLRP3 activation (Rossol et al., 2012).
4.2. Alternative NLRP3 inﬂammasome pathway
Recently, work on human monocytes has identiﬁed an alternative
pathway of NLRP3 inﬂammasome activation leading to IL1β secretion
from living cells (Gaidt & Hornung, 2017). Although the alternative
inﬂammasome activates NLRP3-ASC-Caspase-1, it does not display
classical inﬂammasome characteristics like pyroptosis, and is not de-
pendent on K+ efﬂux (Fig. 2, right panel). Rather, in the alternative
pathway, the axis of Toll-like receptor (TLR) -4, (TLR4-TRIF-RIPK1-
FADD-CASP8) which signals upstream of NLRP3, is important for
IL1β responses in human monocytes (Gaidt et al., 2016). Additional
studies have supported an alternative NLRP3 inﬂammasome (Wolf
et al., 2016; Zanoni et al., 2016). Oxidized 1-palmitoyl-2-
arachidonyl-sn-glycero-3-phosphorylcholine (oxPAPC), a common
oxidized lipid in inﬂammation and a damage molecule that mimics
LPS, can induce Il1β secretion in murine dendritic cells through a
caspase-11-dependent Nlrp3 inﬂammasome without inducing
pyroptosis. N-acetylglucosamine (NAG), a sugar subunit of peptido-
glycan present in Gram-positive bacteria, induces IL1β secretion
independently of potassiumefﬂux andpyroptosis, a pattern supporting
the alternative NLRP3 inﬂammasome (Wolf et al., 2016). The presence
of NAG in the cytoplasm is detected by the glycolytic enzyme
hexokinase. Following NAG detection, hexokinase is inhibited and
detaches from the outer mitochondrial membrane. The dissociation of
hexokinase from the mitochondria is sufﬁcient to stimulate NLRP3
inﬂammasome activation and IL1β secretion (Wolf et al., 2016).
Hexokinase thus, acts as a pattern recognition receptor, alerting the
cell to the presence of microbial products in phagosomes thereby sug-
gesting interplay between metabolism and pathogen detection.
5. What about the NLRP12 inﬂammasome?
NLRP12 (also called MONARCH-1, PYPAF-7 or NALP12) is one of the
ﬁrst described NLR proteins. However, its physiological role remains
controversial, since, by usingdifferentmodels and technical approaches,
both pro- and anti-inﬂammatory properties of NLRP12 have been re-
ported. Indeed, in 2002, Wang et al. performed transient expression
studies in different cell lines and showed that NLRP12 activates NF-κB
and caspase-1 (Wang et al., 2002). More speciﬁcally, co-expression of
ASC with increasing amounts of NLRP12 in HEK293T cells resulted in a
concentration-dependent increase in NF-κB activity. The expression of
NLRP12 together with pro-caspase-1, pro-Il1β, and ASC in COS7L cells
showed that NLRP12 and ASC synergistically activate pro-caspase-1.
These in vitro studies also revealed that NLRP12 co-localizes with ASC
punctate structures in the cytoplasm; however, no interaction between
NLRP12 and ASC could be shown by co-immunoprecipitation experi-
ments (Wang et al., 2002). Several subsequent studies have argued for
an anti-inﬂammatory role of NLRP12. A study performed in human
PBMCs and in THP1 cells infected with Mycobacterium tuberculosis,
showed that NLRP12 inhibits IRAK-1 phosphorylation, repressing
TLR signalling, thus resulting in negative regulation of canonical NF-κB
signalling (Arthur, Lich, Aziz, Kotb, & Ting, 2007; Lich et al., 2007;
Williams et al., 2005). Two years later, the same team showed
that NLRP12 also induces proteasome-mediated degradation of
NF-κB Inducing Kinase (NIK) (Lich et al., 2007), thereby inhibiting
“noncanonical” NF-κB signalling. Similarly, another in vitro study
showed that NLRP12 strongly inhibits NF-κB activation induced by
p65 (Jéru et al., 2008), whereas the study of Nlrp12−/− micedemonstrated that Nlrp12, on the one hand, suppresses colon inﬂam-
mation and tumorigenesis through negative regulation of non-
canonical NF-κB signalling (Allen et al., 2012; Zaki et al., 2011);
Nlrp12 on the other hand exerted no effect on Il1β and Il18 production
(Ulland et al., 2016). Whether or not NLRP12 acts as a part of an
inﬂammasome component and its precise role requires further
validation.
6. The Pyrin inﬂammasome
Inﬂammasomes can also assemble around proteins that contain PYD
domains but do not belong to the NLRP family. The pyrin protein
contains an N-terminal PYD domain, a basic leucine zipper domain
(b-ZIP), a B-box domain that through multiple ﬁnger-like protrusions,
makes tandem contacts with possible target molecules, and a coiled-
coiled domain, which consists of α-helices wrapped around each
other to form a supercoil and a C-terminal B30.2 domain (Gumucio
et al., 2002) (Fig. 4A). Pyrin is part of a larger family of antiviral proteins
termed TRIM (TRIpartite Motif) which are involved in innate immunity
(reviewed in (Nisole, Stoye, & Saïb, 2005)). Pyrin is strongly expressed
in neutrophils, and to varying degrees in monocytes, eosinophils and
dendritic cells, but not in lymphocytes (Centola et al., 2000; Tidow
et al., 2000). Pyrin is also expressed, but to a lesser degree, in ﬁbroblasts
from synovium, peritoneum and skin (Diaz et al., 2004; The
International FMF Consortium, 1997). In vitro differentiation of human
monocytes to macrophages down-regulates the expression of the
gene coding for pyrin,MEFV (standing forMEditerranean FeVer because
of its involvement in the autoinﬂammatory disease called familial Med-
iterranean fever or FMF— see below) (Seshadri, Duncan, Hart, Gavrilin,
& Wewers, 2007). Various mediators like LPS, pro- and anti-
inﬂammatory cytokines and colchicine (the drug of choice for FMF
patients) have been shown to modulateMEFV expression. Their effect
depends on the cell type and the experimental conditions used
(Centola et al., 2000).
The involvement of MEFV in the pathogenesis of FMF was the ﬁrst
evidence suggesting that pyrinmay play an important role in inﬂamma-
tion. Further indirect evidence supported this hypothesis: ﬁrst of all,
pyrin expression is restricted to cells of innate immunity (neutrophils
and monocytes), which are the main cellular mediators of inﬂamma-
tion. Secondly, the PYD domain of pyrin is commonly found in other
proteins implicated in inﬂammation and apoptosis (i.e. several NLRPs
and ASC). In addition, using a yeast two-hybrid screen, pyrin was
found to associate through PYD: PYD homotypic interactions with ASC
(Masumoto et al., 1999; Richards et al., 2001). While contradictory hy-
potheses have been formulated concerning pyrin’s role and its capacity
to form an inﬂammasome, recent advances have shown the molecular
interactions leading to a pyrin inﬂammasome (Xu et al., 2014). More
than ten years ago, a two-hybrid screen identiﬁed the highly conserved
14-3-3τ and 14-3-3ε proteins as partners of pyrin. This was not the case
-for a pyrin isoform lacking the domain encoded by exon 2 and gener-
ated by alternative splicing (Jéru et al., 2005; Papin et al., 2000). More
precisely, it was shown that pyrin could be phosphorylated and that
its interaction with 14-3-3 proteins depends on the phosphorylation
status of 3 serine residues (i.e. Ser208, Ser209 and Ser242) clustered
in a pyrin region encoded by exon 2 and located downstream of the
PYD domain, with Ser242 being the major determinant for this
interaction (Jéru et al., 2005). This data represents the missing link re-
quired to explain the observation made in 2014 by Xu et al. (2014)
that bacterial toxins such as Clostridium difﬁcile toxins A and B activate
pyrin: these toxins inactivate the swhitch-1 region of the RhoA GTPase
(Xu et al., 2014) whereas, as shown recently, RhoA activates the serine-
threonine kinases PKN1 and PKN2 that bind and phosphorylate pyrin at
residues 208 and 242 (Park, Wood, Kastner, & Chae, 2016).
The current model suggests that these toxins activate pyrin through
dephosphorylation, thereby preventing the binding of 14-3-3 proteins
to pyrin. As a consequence, such “free” pyrin is able to participate in a
Fig. 4.AModel for pyrin activation. A. The serine residues Ser208, Ser209 and Ser242 in human pyrin are phosphorylated by the PKN1 and PKN2 kinases, which are RhoA effectors. 14-3-3
proteins interact with the phosphorylated serines and maintain pyrin in a resting/inactive state. B. Bacterial toxin-mediated modiﬁcations inactivate RhoA, preventing PKN1 and PKN2
activation. Consequently, the serine residues are not phosphorylated and 14-3-3 proteins fail to interact with pyrin leading to its activation. Activated pyrin interacts with ASC and pro-
caspase-1, forming a pyrin inﬂammasome that activates caspase-1, leading to proteolytic cleavage of pro-IL1β and pro-IL18. The mature forms (IL1β and IL18) are then secreted and
induce inﬂammation. PKN1 (protein kinase N1), PKN2 (protein kinase N2), RhoA (Ras homolog gene family, member A).
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whereas the binding of 14-3-3 proteins to phosphorylated pyrin
locks pyrin into an inactive state. This model is strongly supported
by the recent report on families with a dominantly inherited
autoinﬂammarory disease due to a missense mutation involving
Ser242 of pyrin (p.S242R). This severe condition, called PAAND
(Pyrin-Associated Autoinﬂammation with Neutrophilic Dermatosis,
see below), in fact results from a constitutive loss of interaction of the
mutant pyrin with 14-3-3 proteins (Masters et al., 2016). Other Rho-
inactivating toxins, all of which modify a switch-I residue of members
of the Rho subfamily and activate pyrin inﬂammasome, include the
Vibrio parahaemolyticus VopS, Histophilus somni IbpA and Clostridium
botulinum C3 toxins. Pyrin, therefore, senses bacterial virulence through
the effect of Rho inactivation rather than through a bacterial-speciﬁc
signal (Xu et al., 2014). Microtubule dynamics are also important in
pyrin activation and microtubule-targeting drugs like colchicine inhibit
pyrin inﬂammasome formation without affecting the pyrin phosphory-
lation status (Gao, Yang, Liu, Wang, & Shao, 2016). Interestingly,
colocalisation of pyrin with actin has also been described, and recently,
aberrant actin depolymerization was shown to trigger the activation of
the pyrin inﬂammasome (Kim et al., 2015). These data strongly suggest
that perturbations of the cytoskeleton structure may also impact the
pyrin inﬂammasome.
7. Molecular pathology of the NLRP3 inﬂammasome
In the early 2000s, before the discovery of the role of NLRP3 in an
inﬂammasome, germline mutations in NLRP3 (also known as PYPAF1or CIAS1), coding for a protein called cryopyrin, have been implicated
in two autosomal dominant disorders: Familial Cold Autoinﬂammatory
Syndrome (FCAS; OMIM #120100) and Muckle-Wells Syndrome
(MWS;OMIM#191900) (Hoffman et al., 2001). Secondarily,NLRP3mu-
tations were also identiﬁed in Neonatal-Onset Multisystem Inﬂamma-
tory Disease (NOMID), also known as Chronic Infantile Neurological
Cutaneous and Articular syndrome (CINCA; OMIM #607115)
(Aksentijevich et al., 2002; Feldmann et al., 2002). Previously described
as distinct entities, all these disorders caused byNLRP3 gain-of-function
mutations are now named Cryopyrin-Associated Periodic Syndromes
(CAPSs, also known as cryopyrinopathies) and are part of the spectrum
of the same systemic autoinﬂammatory condition. Cardinal clinical
signs are fever, urticaria-like rash, arthralgia, sensorineural deafness
and possibly amyloid A amyloidosis. Usually, familial cases are observed
in patients with FCAS and MWS, and sporadic cases (due to de novo
NLRP3mutations) in NOMID patients. Most of the mutations identiﬁed
in CAPS patients are missense variants located in the NACHT domain
of NLRP3. However, mutations involving the same amino acid residue
can be associatedwith either a severe form of the disease or amild phe-
notype. Moreover, it has been shown that NOMID andMWS can be due
to post-zygotic mosaicNLRP3mutations thatwere identiﬁed in circulat-
ing leukocytes (Nakagawa et al., 2015; Omoyinmi et al., 2014; Saito
et al., 2005; Tanaka et al., 2011). Recently, somatic NLRP3 mutations
have been reported in few patients with late onset CAPS, probably
reﬂecting the late occurrence of a mutational event in target cells of
this disease (Mensa-Vilaro et al., 2016; Zhou et al., 2015).
Peripheral bloodmononuclear cells (PBMCs) from CAPS patients are
characterized by a constitutively active inﬂammasome, as revealed by
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Lankester, Ten Cate, & van Dissel, 2004). Noteworthy, monocytes
harbouring the NLRP3 mutations associated with CAPS secrete IL1β
without prior stimulation. Adherent monocytes from healthy donors
require 24h treatment with LPS for IL1β secretion, whereas the kinetics
of IL1β secretion from CAPS-monocytes are faster even after a short 2h
treatment (Agostini et al., 2004). The proposed underlying mechanism
leading to inﬂammasome activation suggests that several mutations in
the NACHT domain of the protein prevent the NLRP3 repression that
is normally achieved by signals like intracytoplasmic cAMP (Lee et al.,
2012). Indeed, high levels of cAMP have been shown to inhibit NLRP3
by at least twomechanisms: (i) through NLRP3 ubiquitination and sub-
sequent degradation of the protein (Yan et al., 2015), and (ii) through
activation of protein kinase A that, in turn, phosphorylates Ser295 lo-
cated in the NACHT domain, thereby inhibiting the NLRP3 ATPase activ-
ity required for assembly of NLRP3-ASC complexes (Mortimer, Moreau,
MacDonald, & Chadee, 2016). Although the potential impact of NLRP3
mutations on the ubiquitination state of cryopyrin remains to be
assessed, several CAPS mutations have indeed been shown to prevent
phosphorylation of Ser295 (Mortimer et al., 2016). Recently NEK7, a
member of the NIMA (Never In Mitosis gene A)-related kinases, has
been shown to be an important factormediating NLRP3 oligomerization
and ASC speck formation downstream of potassium efﬂux (He, Zeng,
Yang, Motro, & Núñez, 2016; Schmid-Burgk et al., 2016; Shi et al.,
2016). In this regard, macrophages from mice harbouring the CAPS-
associated p.R258W mutation (p.R260W in humans) with a Muckle-
Wells phenotype do not require potassium efﬂux for inﬂammasome
activation (Meng, Zhang, Fuss, Kitani, & Strober, 2009), but require
NEK7 for caspase-1 activation, thereby suggesting that, in the presence
of this mutation, NLRP3 associates with NEK7 in the absence of
potassium efﬂux (He et al., 2016).
8. Molecular pathology of NLRP12
NLRP12 transcripts have been found in human peripheral blood
leukocytes, mainly in eosinophils and in granulocytes, and to a much
lesser extent in monocytes, whereas no transcript was detected in T or
B cells (Wang et al., 2002). Extremely rare NLRP12 mutations have
been identiﬁed in a group of autoinﬂammatory diseases known as
NLRP12-associated periodic fevers syndromes (NLRP12-APS), a disease
condition transmitted in an autosomal dominant manner and
characterized by the association of cold-induced urticarial rash, fever,
arthralgia and myalgia (Borghini et al., 2011; Jéru et al., 2008; Jéru, Le
Borgne, et al., 2011; Xia et al., 2016). Some rare mutations are loss-of-
function mutations (nonsense and frameshift mutations) present in
the heterozygous state in patients (Jéru et al., 2008; Xia et al., 2016).
In a similarmanner to observations in CAPS patients, increased or accel-
erated IL1β secretion from monocytes of NLRP12-APS patients has also
been reported (Borghini et al., 2011; Jéru, Hentgen, et al., 2011). These
results are not in agreement with those obtained in mice carrying a ho-
mozygous inactivation of Nlrp12, in which, Il1β production was not
found to be altered (Ulland et al., 2016). Taken together these data un-
derline the necessity of additional molecular studies in order to further
assess the implication of NLRP12 in human pathology.
9. Molecular pathology of the Pyrin inﬂammasome
MEFV (also known as TRIM20), the gene coding for pyrin, was
identiﬁed as the gene involved in FMF (French FMF Consortium, 1997;
The International FMF Consortium, 1997), the most prevalent
autoinﬂammatory disease condition, transmitted as autosomal
recessive trait among patients of Mediterranean extraction. The most
common mutations (i.e., p.M680I, p.M694V, p.M694I and p.V726A)
are clustered within exon 10 that encodes the C-terminal B30.2/SPRY
domain of the protein, with the M694V/M694V homozygous genotypebeing associated with a high prevalence of renal amyloidosis
(Cazeneuve et al., 1999, 2000; Dewalle et al., 1998).
Onemajor question for many years was to understandwhether FMF
is a recessive disorder due to loss-of-function mutations in pyrin, a
protein with, therefore, anti-inﬂammatory properties, or a dominant
disorder with gain-of-function mutations (with gene-dosage effect) in
the pyrin protein that would then have pro-inﬂammatory properties.
Although the ﬁrst FMF mutations were identiﬁed more than 20 years
ago, it is only just recently that some answers have emerged. First of
all, it is important to remember that the MEFV gene was successfully
identiﬁed through linkage analysis and a positional cloning approach
by two international consortia in 1997 (French FMF Consortium,
1997; The International FMF Consortium, 1997), based on a transmis-
sionmodel assuming that FMF is an autosomal recessive condition. Sev-
eral lines of evidence - including of course those deduced from the
disease phenotype of FMF patients, but also the tissue-speciﬁc expres-
sion of MEFV, as well as results from in vitro studies (Centola et al.,
2000) - strongly suggested that pyrin is implicated in the regulation of
inﬂammatory processes. However, the mechanisms by which this pro-
teinmay regulate such processeswere poorly understood until recently.
Depending on experimental conditions, data have been accumulated in
favor of either an anti-inﬂammatory or a pro-inﬂammatory role for
pyrin. For instance, anti-inﬂammatory properties were ﬁrst deduced
from the phenotype of mice carrying a targeted disruption of pyrin
(Chae et al., 2003). As murine pyrin lacks the C-terminal B30.2 domain
found in humans which contains the main FMF mutations, additional
studies have been performed using the human pyrin (Chae et al.,
2006, 2008, 2011; Yu et al., 2007). In addition, the fact that FMF was
ﬁrst classically considered as a recessive disorder has raised other im-
portant questions with regard to the underlying pathophysiological
mechanisms. First, it is striking to note that, except in extremely rare in-
stances, the FMF-associated sequence variants are missense mutations,
most of them being conservative (i.e. replacing an amino acid by an-
other onewith similar biochemical properties in terms of charge, hydro-
phobicity and size). In other words, there is virtually no obvious loss-of-
function mutation in FMF, like for instance splicing defects, deletions,
frameshift or nonsensemutations, which are expected to occur in reces-
sive conditions. Second, a signiﬁcant number of patients with a clinical
diagnosis of FMF carry only a single mutated MEFV allele. Third, al-
though several studies showed that peripheral blood leukocytes from
FMF patients have reducedMEFVmRNA levels as compared to controls
(Notarnicola et al., 2002; Ustek et al., 2007), a higher expression of the
pyrin protein in neutrophils of FMF patients carrying one or two mu-
tatedMEFV alleles was found in another study, as compared to controls
and to non-FMF patients with active inﬂammation (Booty et al., 2009).
This latter study also showed a trend toward higher expression levels
ofMEFV transcripts in FMFpatients (as compared to controls). Taken to-
gether, these data raise the question as to whether the pyrin mutations
found in FMF patients would be gain-of-function mutations with a
gene-dosage effect consistent with a semi-dominantmode of transmis-
sion of the disease. In fact, additional studies strongly support such hy-
pothesis of gain-of-function mutations in pyrin. This is the case for the
data obtained from the generation of knock-in mice harboring mutant
human B30.2 domains (Chae et al., 2011). The report of an FMF patient,
homozygous for the p.M694V mutation, and who developed a chronic
myelomonocytic leukemia leading to an uncontrolled inﬂammatory
syndrome, also strongly argues for a pro-inﬂammatory role of the
wild-type protein, with the p.M694V mutation acting as a gain-of-
function mutation (Awad et al., 2015).
With the recent discovery of the pyrin inﬂammasome, questions re-
garding the causality of the identiﬁed MEFV sequence variations have
become even more important as toxins can activate the pyrin
inﬂammasome in both humans and mice, thereby suggesting that the
B30.2 domain (absent in mice) is not required for activation (Gao
et al., 2016; Van Gorp et al., 2016). The pyrin inﬂammasome requires
microtubules for its function, although their exact role remains to be
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which is also the drug of choice for FMF, has been shown to abolish
pyrin-mediated IL1β secretion from C. difﬁcile-infected mouse macro-
phages or PBMCs from healthy donors, from CAPS patients or from
other patients with an autoinﬂammatory disease (Van Gorp et al.,
2016). Surprisingly however, PBMCs from FMF patients in the presence
of colchicine continued to secrete signiﬁcant levels of IL1β and IL18 in
response to C. difﬁcile toxin A, thereby suggesting that the FMF muta-
tions remove the dependency of pyrin for microtubules. As several
pathogens use microtubule dynamics to their advantage, the authors
speculate that FMFmutations may confer protection to endemic patho-
gens (Van Gorp et al., 2016). Along similar lines, Jamilloux et al showed
that monocytes from FMF patients have an increased ability to respond
to low doses of a pyrin-activating stimulus as compared to monocytes
from healthy donors (Jamilloux et al., 2017).
More recently, another phenotype distinct from FMF and transmit-
ted in an autosomal dominant manner was found to be associated
with novel MEFV mutations located within exon 2 and present in the
heterozygous state in the patients (Masters et al., 2016). This disease,
named PAAND for Pyrin-Associated Autoinﬂammation with Neutro-
philic Dermatosis, was ﬁrst described in a large family with the p.
S242R mutation (see above, paragraph 6). This mutation concerns one
of the amino acids that are phosphorylated and critical for 14-3-3 bind-
ing (Jéru et al., 2005; Masters et al., 2016). A second family with PAAND
was subsequently reported. The patients were shown to carry the
c.730GNA (p.E244K) mutation also located in MEFV exon 2. Similarly
to the p.S242R mutation, the p.E244K mutation displays a reduced
phosphorylation of the 14-3-3 binding site and a reduced 14-3-3 bind-
ing (Moghaddas et al., 2017). These two observations further support
the pro-inﬂammatory role of pyrin.
10. NLRP3, NLRP12 and pyrin in common
diseases with an inﬂammatory component
10.1. NLRP3 in common diseases and inﬂammatory disease susceptibility
10.1.1. NLRP3 in common diseases
A number of metabolic DAMPs have been shown to activate the
NLRP3 inﬂammasome in common multifactorial chronic inﬂammatory
diseases (Abderrazak, Syrovets, et al., 2015; Freeman & Ting, 2016;
Grant & Dixit, 2013; Haneklaus & O’Neill, 2015; Hoseini et al., 2017;
Ralston, Lyons, Kennedy, Kirwan, & Roche, 2017; Rheinheimer, de
Souza, Cardoso, Bauer, & Crispim, 2017; Sepehri et al., 2017; So &
Martinon, 2017). Among them, we will focus on Alzheimer, Type 2
diabetes (T2D), obesity, gout and atherosclerosis.
Alzheimer's disease is a neurodegenerative disease associated with
the presence of insoluble amyloid β (Aβ) aggregates that lead to neuro-
nal death. It has been shown that Aβ particles activate the NLRP3
inﬂammasome in resident microglia cells, leading to caspase-1 activa-
tion and IL1β secretion through lysosomal damage (Gold & El Khoury,
2015). The release of pro-inﬂammatory cytokines from microglia cells
surrounding Aβ-containing senile plaques activate additional microglia
cells as well as astrocytes, leading to neurotoxic factors and pro-
inﬂammatory cytokine production, which in turn contribute to
neuronal dysfunction and cell death (Edison et al., 2008; Halle et al.,
2008; Heppner, Ransohoff, & Becher, 2015; Liu & Chan, 2014; Rossi &
Bianchini, 1996; Rubio-Perez & Morillas-Ruiz, 2012).
T2D, is characterized by progressive dysfunction of pancreatic islet
beta-cells leading to insulin resistance and high plasma glucose concen-
trations. Islet amyloid polypeptide (IAPP), a hormone secreted in paral-
lel with insulin, causes amyloid deposits in the islets and thus further
induces beta cell damage. As shown by Masters et al., IAPP activates
the Nlrp3 inﬂammasome in mouse macrophages and dendritic cells,
resulting in Il1β secretion, providing a mechanistic link for Il1β activa-
tion in T2D (Masters et al., 2010). Accordingly, transgenic mice overex-
pressing the human IAPP show increased Il1β expression in thepancreas, which colocaliseswith amyloid deposits . High concentrations
of glucose alone are not able to prime the NLRP3 inﬂammasome, al-
though in monocyte-like THP1 cells, high glucose concentrations have
been shown to induce the mRNA expression of pro-inﬂammatory
cytokines (Shanmugam, Reddy, Guha, & Natarajan, 2003). A D-glucose
analogue, 2-deoxy-D-glucose, which blocks glycolysis, is known to
prevent the induction of Il1β expression in LPS-primed mouse macro-
phages, suggesting that metabolism of glucose is required for
inﬂammasome activation (Masters et al., 2010). Consistent with these
data, in diabetic rats, silencing of Nlrp3 has been shown to improve
diabetic cardiomyopathy and inﬂammatory status (Luo et al., 2014).
Obesity is a multifactorial condition characterized by fat accumula-
tion and hypertrophy of adipose tissue due to impairedmetabolism, ge-
netic and environmental factors. In most cases, fat accumulation is also
present in the liver, skeletal muscle, and pancreas leading to chronic
low-grade inﬂammation. Increased glucose and free fatty acid levels in
the plasma of obese people links obesity to insulin resistance and
metabolic syndrome (Hotamisligil, 2006; Odegaard & Chawla, 2008).
High glucose levels increase IL1B expression and secretion in human
andmurine adipose tissue through activation of TXNIP, a protein linking
oxidative stress with the activation of inﬂammasome (Koenen et al.,
2011; Zhou et al., 2010). Palmitate and stearate, both saturated fatty
acids, activate the NLRP3 inﬂammasome in primed murine and
human macrophages (L’homme et al., 2013; Wen et al., 2011). Con-
versely, the unsaturated oleate and linoleate block NLRP3-mediated
IL1β secretion and prevent NLRP3 activation induced by saturated
fatty acids in human monocytes/macrophages (L’homme et al., 2013;
Wen et al., 2011). Interestingly, it has been shown that palmitate, but
not the unsaturated palmitoleate, activates caspase 4/5 -mediated
pyroptosis in monocytes from obese-diabetic patients, thereby contrib-
uting to the release of IL1β and IL18 (Pillon et al., 2016). Ceramides, also
present at high concentrations in obese adipose tissue, can also activate
NLRP3. In obese individuals with T2D, calorie restriction and exercise-
mediated weight loss reduce NLRP3 and IL1B expression in adipose
tissue, lower glycemia and decrease inﬂammation, further supporting
links between lipotoxicity and the NLRP3 inﬂammasome (Rheinheimer
et al., 2017; Vandanmagsar et al., 2011).
Gout, another common inﬂammatory disease, is characterized by in-
creased levels of uric acid and deposition of monosodium urate crystals
in the joints. Deposition of crystals is accompanied by a strong pro-
inﬂammatory response characterized mainly by IL1β secretion.
Internalization of MSU crystals by resident macrophages activates
NLRP3 inﬂammasome, with neutrophil recruitment in the joint area
(Martinon, Petrilli, Mayor, Tardivel, & Tschopp, 2006).
Atherosclerosis, the underlying cause of several cardiovascular
diseases, is another common chronic condition characterized by chronic
low-grade inﬂammation, in which the NLRP3 inﬂammasome has been
implicated (Duewell et al., 2010). Interactions between lipids and arte-
rial wall cells lead to plaque formation. Lipid-loaded macrophages —
known as foam cells— resulting from uptake of modiﬁed low-density li-
poproteins is a hallmark of atherosclerosis. Oxidized lipids present in
the local environment, hypoxia, necrosis and inﬂammatory cytokine se-
cretion lead to lesion development and vessel stenosis. Plaque rupture
can be responsible for tissue ischemia andmajor events includingmyo-
cardial infarction or stroke. An experimental ApoE−/−mouse model,
which develops hypercholesterolemia and spontaneous atherosclerosis,
crossedwithNlrp3−/−, Asc−/− or caspase-1−/−mice did not support
the implication of Nlrp3 in the pathophysiology of atherosclerosis
(Menu et al., 2011). However, it has been shown that cholesterol
crystals, which are present in early atherosclerotic lesions, activate the
Nlrp3 inﬂammasome by inducing lysosomal damage in LPS-primed
mousemacrophages. Similarly, cholesterol crystals injected intraperito-
neally induced an acute inﬂammation that was impaired in mice
deﬁcient in inﬂammasome components (Duewell et al., 2010).
These results were supported by the attenuated early atherosclerosis
in mice deﬁcient in the low-density lipoprotein receptor (Ldlr−/−)
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cells (Duewell et al., 2010). Activation of complement has been
suggested as a possible link between cholesterol crystals and NLRP3
activation (Samstad et al., 2014). Furthermore, the local acidic environ-
ment in atherosclerotic areas is now recognized as a novel endogenous
DAMP for NLRP3 inﬂammasome activation in immune cells (Rajamäki
et al., 2013). Necrosis, also present in atherosclerotic lesions, activates
the NLRP3 inﬂammasome through the release of DAMPs from necrotic
cells (Li, Ambade, & Re, 2009).
10.1.2. NLRP3 in inﬂammatory disease susceptibility
An intronic 42 base-pair variable number tandem repeat polymor-
phism (rs74163773) of NLRP3 has been shown to be associated with
susceptibility to essential hypertension in a Japanese study (Omi et al.,
2006). In healthy adults carrying this genotype, the transcript levels of
NLRP3 were higher, suggesting that this tandem repeat is a functional
polymorphism for hypertension. However, in the same study, a repli-
cate panel from a random population (268 men and 162 women)
showed signiﬁcant association of this polymorphismwithmean systolic
blood pressure, which was slightly elevated in men, but not in women
(Omi et al., 2006). A GWASmeta-analysis performed in order to identify
genetic variants associated with plasma levels of C-reactive protein
(CRP, a marker of chronic inﬂammation) in 82725 subjects of
European ancestry, including incident cases with cardiovascular events,
identiﬁed 18 signiﬁcant loci. An NLRP3 polymorphism (rs12239046)
was part of them, but neither the NLRP3 locus nor 11 other loci were
conﬁrmed in a replication panel of the study (Dehghan et al., 2011).
SeveralNLRP3polymorphismswere analysed in targeted association
studies of common diseases. These studies performed in subjects from
the Chinese Han-population suggested an association of NLRP3 SNPs
with occurrence of coronary artery disease (for the rs10754558)
(Zhou et al., 2016), with a risk of late onset of Alzheimer's disease (for
the rs2027432) (Tan et al., 2013), and with ischemic stroke susceptibil-
ity (for the rs10754558) (Zhu et al., 2016). However, a recent study of
atherosclerotic plaque from the carotid artery performed in Swedish pa-
tients with ischemic cerebrovascular disease compared to healthy con-
trols failed to ﬁnd signiﬁcant associations between the NLRP3 SNPs
(rs6672995 and rs10733113) and NLRP3 expression in atherosclerotic
plaque (Paramel Varghese et al., 2016). In summary, although the in-
volvement of NLRP3 mutations in autoinﬂammatory diseases is
established, association between frequent NLRP3 polymorphisms and
susceptibility to common diseases failed to be clearly demonstrated.
10.2. NLRP12 in common diseases and inﬂammatory disease susceptibility
In mice, Nlrp12 maintains intestinal homeostasis, attenuates colon
inﬂammation and tumorigenesis, through negative regulation of NF-
κB and MAPK pathways (Allen et al., 2012). Mice lacking Nlrp12 are
highly susceptible to colitis and colitis-associated colorectal cancer
(Allen et al., 2012; Zaki et al., 2011), and hyper-resistant to Salmonella
typhimurium infection (Zaki, Man, Vogel, Lamkanﬁ, & Kanneganti,
2014) suggesting that Nlrp12 is a negative regulator of innate
immunity. Nlrp12-deﬁcient mice present a dysbiotic microbiome and
increased colonic basal inﬂammation, which were reversed by antibod-
ies targeting Tnf and the Il6 receptor or by administration of
Lachnospiraceae strains (Chen et al., 2017). Nlrp12 has also been
shown to play a role in host defences against bacterial pathogens.
Nlrp12 is indeed able to detect Yersinia pestis (causal for plague).
Yersinia pestis infection induces Nlrp12 inﬂammasome activation,
leading to Il18 production and clearance of the infection. Following in-
fection, Nlrp12-deﬁcient mice showed higher mortality rates and
lower secretion of Il18, Il1β and Ifn-γ (Vladimer et al., 2012). In humans,
NLRP12 expression was shown to be signiﬁcantly down-regulated in
patientswith active ulcerative colitis, as compared to patientswith inac-
tive ulcerative colitis or healthy controls (Chen et al., 2017). In malaria
infected-patients, both NLRP12 and NLRP3 inﬂammasomes weredetected, suggesting that NLRP12 may play a role in the regulation of
IL1β production and in the hypersensitivity to secondary bacterial infec-
tion during malaria (Ataide et al., 2014). Of note, increased NLRP12
mRNA and protein expression was found to be associated with prostate
cancer (Karan, Tawﬁk, & Dubey, 2017).
10.3. Pyrin in common diseases and inﬂammatory disease susceptibility
The fact that FMF-associated mutations are more frequent in Medi-
terranean populations has led to the hypothesis that mutations may
confer a selective advantage, possibly a defence mechanism against en-
demic bacterial or viral infections (Aksentijevich et al., 1999; Jamilloux
et al., 2017). Interestingly, recent studies have shown that Yersinia
pestis prevents innate immune responses by inhibiting the pyrin
inﬂammasome (Chung et al., 2016; Ratner et al., 2016). These studies,
however, did not implicate the NLRP12 inﬂammasome in Yersinia pestis
recognition (Ratner et al., 2016; Vladimer et al., 2012). Yersinia pestis
harbors a sophisticated virulence system in which the GAP effector
YopE is detected by immune cells; however, YopM blocks the response
by inhibiting the pyrin-mediated inﬂammasome (Ratner et al., 2016);
indeed, YopMactivates the host kinases PKN1 and PKN2 that phosphor-
ylate pyrin, and as a result Yersinia pestis escapes antibacterial responses
(Chung et al., 2016).
GWAS studies failed to identify disease-associated common variants
inMEFV. Nevertheless, targeted analyses ofMEFV in the Turkish popula-
tion in which FMF mutations are common suggested that the p.M694V
mutation may be a risk factor for ankylosing spondylitis (Zhong, Song,
Wang, Li, & Ma, 2017), inﬂammatory bowel disease (Akyuz et al.,
2013) and Behcet disease (Kirino et al., 2013).
11. Current therapeutic approaches
in inﬂammasome-related pathologies
11.1. Pharmacological inhibitors of NLRP3 inﬂammasome activation
Severalmolecules have been shown to inhibit NLRP3 inﬂammasome
activation (Di Virgilio, 2013; Shao, Xu, Han, Su, & Liu, 2015) but there is
no evidence that they directly inhibit NLRP3. Molecules like sulforaph-
ane and isoliquiritigenin can also inhibit other inﬂammasomes in addi-
tion to NLRP3, or inhibit also general inﬂammatory pathways such as
that of NF-κB (Greaney, Maier, Leppla, & Moayeri, 2016; Heiss,
Herhaus, Klimo, Bartsch, & Gerhäuser, 2001; Honda et al., 2012). The
fenamate class of non-steroidal anti-inﬂammatory drugs (Daniels
et al., 2016) and the β-hydroxybutyrate (Youm et al., 2015) inhibit ion
ﬂuxes. Other inhibitors like Parthenolide, BAY 11-7082, INF39, (Cocco
et al., 2017; He et al., 2014; Juliana et al., 2010) or the 3,4-
methylenedioxy-β-nitrostyrene that inhibits the activity of Src and
Syk kinases (Wang,Wu, &Wu, 2006), have broad anti-inﬂammatory ac-
tivities and equally suppress NF-κB activation (Cocco et al., 2017;
Strickson et al., 2013; Yip et al., 2004). Arglabin, a guaianolide sesquiter-
pene lactone with both anti-inﬂammatory and antitumor activity has
been shown to inhibit the NLRP3 inﬂammasome and atherosclerotic le-
sion formation in high-fat fed ApoE2Kimice (Abderrazak, Couchie, et al.,
2015). MCC950 a diarylsulfonylurea-containing compound which in-
hibits caspase-1 (Perregaux et al., 2001) speciﬁcally inhibits NLRP3
inﬂammasome activation in a mouse model of CAPS and in cells of pa-
tients with Muckle-Wells syndrome (Coll et al., 2015; Dempsey et al.,
2017). It was also shown to be effective in reducing caspase-1-
activation in microglia cells and in atherosclerotic mice models
(Dempsey et al., 2017; van der Heijden et al., 2017); however, its direct
target remains unknown. Recently, the CY-09 compound was shown to
inhibit NLRP3 inﬂammasome assembly and activation through binding
to the NACHT domain of NLRP3 (Jiang et al., 2017). Treatment of mice
with CAPS with CY-09 led to an impressive improvement of the disease
phenotype (Jiang et al., 2017). Furthermore, CY-09 has also been shown
to be successful in blocking the NLRP3 inﬂammasome ex vivo in
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tients with gout (Jiang et al., 2017). It was also successful in reversingmet-
abolic disorders in diabetic mice, strongly supporting the role of NLRP3 in
chronic inﬂammation (Jiang et al., 2017). MicroRNA mir-9, which targets
speciﬁcally NLRP3 has shown promising results in vitro atherosclerosis
models (Wang et al., 2017). Mir-223 (Bauernfeind et al., 2012) which reg-
ulates NLRP3 inﬂammasome activity and is implicated in cholesterol me-
tabolism (Vickers et al., 2014) is another interesting target.
11.2. From colchicine to biotherapies
Colchicine, an alkaloid extract from Colchicum autumnale, is the ﬁrst
line of treatment for FMF patients. The anti-inﬂammatory action of
colchicine is attributed to its capacity to inhibit microtubule polymeri-
zation and thus to alter the adhesion and mobility of leukocytes (Niel
& Scherrmann, 2006). Most patients respond well to colchicine, which
prevents acute symptoms, reoccurrence of episodes and amyloid A
amyloidosis, the major long-term FMF complication (Dinarello, Wolfe,
Goldﬁnger, Dale, & Alling, 1974; Goldﬁnger, 1972; Saatçi et al., 1997;
Zemer et al., 1974; Zemer et al., 1986). Colchicine is a daily lifelong treat-
ment, which should be started as soon as the diagnosis is established
(Grattagliano et al., 2014). A small percentage of FMF patients do not
respond to colchicine or are intolerant due to side effects, particularly
at the gastrointestinal level.
Colchicine is not efﬁcient in CAPS, neither in other autoinﬂammatory
diseases. As a common characteristic of all these diseases concerns the
increased secretion of cytokine members of the proinﬂammatory IL1
family by myelo-monocytic cells, biological treatments targeting IL1
have been tested. These biotherapies include Anakinra (a recombinant
nonglycosylated IL1 receptor antagonist (IL1Ra) that blocks both IL1α
and IL1β), Canakinumab (a fully humanized IgG1 monoclonal antibody
with a high-afﬁnity speciﬁcally to IL1βwhich does not cross-react with
IL1α or IL1Ra) (Hacihamdioglu & Ozen, 2012; Ozen, Bilginer, Aktay
Ayaz, & Calguneri, 2011; Stankovic Stojanovic et al., 2012) and
Rilonacept (a fusion protein consisting of the extracellular domains of
humanized IL1 type 1 receptor and IL1 receptor accessory protein
fused with the FC protein of IgG1, which can bind both IL1β and IL1α)
(Chae, Aksentijevich, & Kastner, 2009; Meinzer et al., 2011; Soriano,
Verecchia, Afeltra, Landolﬁ, & Manna, 2013). Gevokizumab is another
humanized IgG2 monoclonal antibody against IL1βwhich is authorized
for the treatment of rare conditions like pyoderma gangrenosum,
Schnitzler syndrome, chronic non-infectious uveitis or congenital hy-
perinsulinism (Peiró, Lorenzo, Carraro, & Sánchez-Ferrer, 2017).
Since the ﬁrst publication on the efﬁcacy of Anakinra in CAPS, which
changed completely the prognosis of the disease (Hawkins, Lachmann,
& McDermott, 2003), additional randomized trials have conﬁrmed
the clinical efﬁcacy of Anakinra as well as that of Rilonacept and
Canakinumab; the latter have a longer half-life (Goldbach-Mansky
et al., 2006; Hoffman et al., 2008; Lachmann et al., 2009). Several studies
reinforced these phase III results, often with follow-ups of several years,
thereby conﬁrming their safety and efﬁcacy (Goldbach-Mansky et al.,
2008; Imagawa et al., 2013; Koné-Paut et al., 2011; Kuemmerle-
Deschner, Hachulla, et al., 2011; Kuemmerle-Deschner, Tyrrell, et al.,
2011; Kuemmerle-Deschner et al., 2016; Neven et al., 2010; Yokota
et al., 2016). In NLRP12-associated inﬂammation, Anakinra was also
found to be useful, at least transiently (Jéru, Hentgen, et al., 2011). In
addition, FMF patients who do not respond to colchicine, respond to
IL1 inhibition (Ben-Zvi et al., 2017; Hashkes et al., 2012; Koga, Migita,
& Kawakami, 2016; Ozen, Kone-Paut, & Gül, 2017).
11.3. Biotherapies in inﬂammasome mediated-inﬂammatory diseases
The role of the NLRP3 inﬂammasome in common inﬂammatory
diseases has paved the way for the use of anti-IL1 molecules in clinical
trials related to these diseases (https://clinicaltrials.gov/). Several
studies have reported a beneﬁcial effect of Anakinra in acute coronarysyndromes (Abbate et al., 2010, 2013; Morton et al., 2015). Recently
the CANTOS (Canakinumab Anti-inﬂammatory Thrombosis Outcomes
Study) study, which aimed to test the efﬁcacy of canakinumab at
reducing cardiovascular events in 10 061 atherosclerotic patients after
a myocardial infarction, showed that canakinumab at a dose of
150 mg every 3 months leads to a signiﬁcantly lower rate of recurrent
cardiovascular events than the placebo, independent of lipid lowering
(Ridker, Everett, et al., 2017). The clinical use of this drug in the treat-
ment of atherosclerosis is thus promising. However, Canakinumab ad-
ministration was associated with a higher incidence of fatal infections
as compared to placebo. Canakinumab was also efﬁcient in reducing
the incidence of lung cancer and lung cancer mortality, in the same
group of atherosclerotic patients who had no previously diagnosed
cancer (Ridker, MacFadyen, et al., 2017).
IL1 inhibitors have been shown to be efﬁcient in crystal-induced
arthritis and gout (Aouba et al., 2015; Chakraborty et al., 2013; Mitha
et al., 2013; Ottaviani et al., 2013; Pascart & Richette, 2017).
Beta-hydroxybutyrate treatment in mice attenuated both behav-
ioural and inﬂammatory responses (Yamanashi et al., 2017) strongly
suggesting that the use of IL1 inhibitors may be beneﬁcial in neurologic
diseases and neuroinﬂammation in which NLRP3 has been shown to be
implicated (Heneka, 2017; Kaufmann et al., 2017; Pennisi et al., 2017;
Saresella et al., 2016; Song, Pei, Yao, Wu, & Shang, 2017; White,
Lawrence, Brough, & Rivers-Auty, 2017).
12. Conclusion
Danger and pathogen patterns lead to changes in cell homeostasis
which alert the cell to trigger inﬂammasome activation. The complexity
of the mechanisms involved in pathogen detection has further been
underlined by the discovery of the non-canonical inﬂammasomes. De-
spite the important insights in the ﬁeld many questions still remain.
For example, how do pathogens escape innate immune surveillance to
enter the cells and activate caspases? What is the role of the cytoskele-
ton in inﬂammasome activation? How do inﬂammasomes secrete
proinﬂammatory cytokines in the absence of pyroptosis, do various
inﬂammasomes in the same cell regulate the activity of each other,
and many others.
A major outcome of research on rare disorders is the better under-
standing of the pathophysiology of common diseases, as rare disorders
often represent “models of dysfunction” severely affecting a limited num-
ber of biological pathways. This was clearly exempliﬁed by the study of
CAPS, which led to the discovery of NLRP3, the ﬁrst inﬂammasome that
turned out to be a major deregulated pathway in several commonmulti-
factorial disorders with an inﬂammatory component. Mutations in
inﬂammasome receptors lead to autoinﬂammatory diseases and a
deregulation in inﬂammasome activity is associated with the pathology.
And ﬁnally, therapies used in rare autoinﬂammatory diseases are now
successful in common diseases.
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